Fintel reports that Wolfe Research initiated coverage of Tyra Biosciences (NasdaqGS: TYRA) on May 19, 2026, with a “Peer Perform” recommendation. As of May 14, 2026, the average one-year price target for Tyra Biosciences is $51.41 per share, representing a potential upside of 52.23% from its last closing price of $33.77 per share. The projected annual revenue for the company is $21 million, with a non-GAAP EPS forecast of -1.06.
Institutional interest has varied, with 171 funds reporting positions in Tyra Biosciences, a decrease of 56 owners (24.67%) in the last quarter. Total shares owned by institutions rose by 31.03%, now totaling 66.66 million shares. Notably, Ra Capital Management retains the largest stake at 20.51%, while Farallon Capital Management increased its holdings by 204.91%. The put/call ratio stands at 1.74, indicating a bearish outlook.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
